Bio-Rad Laboratories, Inc. (NYSE:BIO) is one of the best debt-free mid-cap stocks to buy according to hedge funds. On February 12, Bio-Rad Laboratories, Inc.

Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full-year ended ...

Moby Strategic Performance Drivers and Operational Context. Management attributed the Q4 gross margin miss to execution- ...

DiVincenzo explained that QX700 is "enabling Bio-Rad to expand its served market and gain share in the entry-level digital PCR segment," and that process chromatography delivered over 20% growth in ...